15785
document
Effects of low and high doses of atorvastatin on arterial compliance . At the beginning of atherosclerosis before evidence of morphological lesions or plaques , vascular distensibility or arterial compliance decreased gradually . This endothelial dysfunction is regarded as an early feature of atherosclerosis . In a randomized , double-blind study design , group 1 ( 12 patients ; 7 males , 5 females ) with serum LDL-C levels higher than 170 mg/dL and without any other risk factor for atherosclerosis received three months of 20 mg/day atorvastatin treatment while group 11 ( 8 males , 4 females ) with the same characteristics received 80 mg/day . Baseline and posttreatment serum lipid fractions and arterial compliance were measured . Arterial compliance was measured noninvasively in the left common carotid artery with color Doppler ultrasound . Atorvastatin reduced total cholesterol ( TC ) , LDL-C , and triglyceride levels by 32 % ( P < 0.001 ) , 40.8 % ( P < 0.001 ) , and 19 % ( P < 0.001 ) , respectively , and increased HDL-C by 6.9 % , ( P = 0.002 ) in the first group . In the second group these reductions were 38.5 % ( P < 0.001 ) , 46.2 % ( P < 0.001 ) , and 26.78 % ( P < 0.001 ) , respectively , and the increase in HDL was 7.8 % ( P = 0.03 ) . It was observed that the decrease in serum TC , LDL-C and triglyceride levels were significantly higher in the second group than the first group . With atorvastatin , the distensibility coefficient ( DC ) and compliance coefficient ( CC ) increased from 18.7 +/- 3.4 to 21.3 +/- 2.9 10 ( -3 ) x kPa ( -1 ) ( P < 0.001 ) and from 0.69 +/- 0.05 to 0.77 +/- 0.03 mm2 x kPa ( -1 ) ( P < 0.001 ) in the first group while they changed from 18.3 +/- 3.6 to 21.9 +/- 3.0 10 ( -3 ) x kPa ( -1 ) ( P < 0.001 ) and from 0.70 +/- 0.04 to 0.81 +/- 0.01 mm2 x kPa ( -1 ) ( P < 0.001 ) respectively , in the second group . DC and CC increased in both groups , but the differences between the groups were not significant . High doses of atorvastatin reduce blood lipid levels more than conventional doses , however , the change in compliance is not dose-dependent . As endothelial dysfunction is regarded as an early feature of atherosclerosis , there would be no need to administer aggressive doses in a patient without any risk factors other than hyperlipidemia .
15786
Intervention_Pharmacological
atorvastatin
15787
Intervention_Pharmacological
atorvastatin treatment
15788
Intervention_Pharmacological
Atorvastatin
15789
Intervention_Pharmacological
atorvastatin
15790
Intervention_Pharmacological
atorvastatin
15791
Outcome_Physical
morphological lesions or plaques
15792
Outcome_Physical
vascular distensibility
15793
Outcome_Physical
arterial compliance
15794
Outcome_Physical
serum LDL-C levels
15795
Outcome_Physical
serum lipid fractions
15796
Outcome_Physical
arterial compliance
15797
Outcome_Physical
Arterial compliance
15798
Outcome_Physical
reduced total cholesterol ( TC )
15799
Outcome_Physical
LDL-C
15800
Outcome_Physical
triglyceride levels
15801
Outcome_Physical
increased HDL-C
15802
Outcome_Physical
increase in HDL
15803
Outcome_Physical
decrease in serum TC
15804
Outcome_Physical
LDL-C
15805
Outcome_Physical
triglyceride levels
15806
Outcome_Physical
distensibility coefficient ( DC )
15807
Outcome_Physical
compliance coefficient ( CC ) increased
15808
Outcome_Physical
DC
15809
Outcome_Mental
CC
15810
Outcome_Physical
reduce blood lipid levels
15811
Participant_Condition
12
15812
Participant_Condition
7 males
15813
Participant_Condition
5 females
15814
Participant_Condition
serum LDL-C levels
15815
Participant_Condition
atherosclerosis
15816
Participant_Condition
8 males
15817
Participant_Condition
4 females